RecruitingNCT07435467

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER): a Multicenter, Observational, 3-arms, Prospective Study

Sponsor

Istituto Nazionale di Ricovero e Cura per Anziani

Enrollment

400 participants

Start Date

Apr 9, 2025

Study Type

OBSERVATIONAL

Conditions

Alzheimer Disease Old Age; Dementia

Summary

The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.

Eligibility

Min Age: 65 Years

Inclusion Criteria4

GROUP 1: Patients hospitalized for acute neurological disorders
Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis
inpatients with diagnosis of major neurocognitive disorder according to DSM-5 criteria (2013)
inpatients with non-neurological diseases

Exclusion Criteria8

no informed consent
GROUP 2: Patients hospitalized for non-neurological diseases with dementia
Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis
no informed consent
GROUP 3: Patients hospitalized for non-neurological diseases without dementia
inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis
diagnosis of dementia
no informed consent